REGN Regeneron Pharmaceuticals Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:32
Aug 17
Aug 17
Notes Q2 aggregate fund value decrease
Notes the stock saw one of the largest aggregate value decreases across 93 funds in Q2 13F filings.
MED
11:28
Aug 17
Aug 17
A news wire reports a broad list of price target increases across dozens of stocks from various.
A news wire reports a broad list of price target increases across dozens of stocks from various analysts, with no directional commentary or personal market views expressed.
14:00
Aug 04
Aug 04
Pfizer highlights its bispecific's Phase 2 data against Regeneron's ivonescimab, suggesting a potential competitive advantage.
HIGH
11:40
Jul 31
Jul 31
A news wire reports a broad wave of price target increases across multiple stocks from various.
A news wire reports a broad wave of price target increases across multiple stocks from various analysts, with no explicit directional calls made by the account itself.
05:37
Jul 31
Jul 31
JPMorgan raises its price target on Regeneron Pharmaceuticals to 900 dollars from 850 dollars.
JPMorgan raises its price target on Regeneron Pharmaceuticals to 900 dollars from 850 dollars, signaling a more bullish outlook on the stock.
12:30
Jul 30
Jul 30
Management expresses a bullish outlook on the pipeline, including multiple launches and readouts ahead, while noting moderating growth for Dupixent later in the year.
HIGH
11:54
Jul 30
Jul 30
Premarket movers report shows mixed earnings reactions with Meta sliding 8% on disappointing.
Premarket movers report shows mixed earnings reactions with Meta sliding 8% on disappointing outlook, Microsoft jumping 9% on strong cloud growth, and numerous other stocks moving on quarterly results and guidance changes.
10:54
Jul 30
Jul 30
Regeneron reports strong second quarter 2026 earnings with 17% revenue growth and record.
Regeneron reports strong second quarter 2026 earnings with 17% revenue growth and record Dupixent sales of 6 billion dollars.
10:44
Jul 30
Jul 30
Regeneron reports strong Q2 2026 earnings with adjusted EPS of 14.29 dollars beating estimates.
Regeneron reports strong Q2 2026 earnings with adjusted EPS of 14.29 dollars beating estimates of 10.30 dollars and revenue of 4.291 billion dollars topping expectations.
22:34
Jul 26
Jul 26
Peak earnings season begins with 177 S&P 500 companies reporting Q2 results this week.
Peak earnings season begins with 177 S&P 500 companies reporting Q2 results this week, including mega caps like Apple, Amazon, and Microsoft.
19:16
Jun 29
Jun 29
Eli Lilly and Regeneron are among the first companies selected for an FDA initiative.
Eli Lilly and Regeneron are among the first companies selected for an FDA initiative to expedite review of new manufacturing facilities, as reported by CNBC.
18:54
Jun 29
Jun 29
Eli Lilly and Regeneron are among the first companies selected for an FDA initiative to speed.
Eli Lilly and Regeneron are among the first companies selected for an FDA initiative to speed review of new manufacturing facilities, as reported by CNBC.
23:29
May 23
May 23
The tweet references Rezpeg (likely REGN's pipeline candidate) with data across thousands.
The tweet references Rezpeg (likely REGN's pipeline candidate) with data across thousands of patients and multiple indications, but lacks a forward-looking directional view or trade call.
HIGH
12:56
May 08
May 08
Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis.
Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis, including a biologic-refractory trial no pharma giant has run, could drive over $5B in peak sales and make NKTR a glaring M&A candidate at current prices.
HIGH
20:30
Apr 30
Apr 30
Repatha new-to-brand prescriptions surged 44% in Q1, driven by recent positive cardiovascular outcomes data in primary prevention, signaling stronger uptake. — Amgen's momentum is a direct challenge to Regeneron's Praluent, suggesting Amgen is winning in the PCSK9 class based on superior outcomes data.
MED
12:30
Apr 29
Apr 29
Management tone is positive, highlighting strong Q1 results with double-digit growth and a robust pipeline, with expectations for continued momentum.
HIGH
12:00
Apr 29
Apr 29
Biogen views Regeneron's GA candidate as a potential competitor, but notes its systemic delivery mechanism and unproven proof-of-concept as potential weaknesses.
HIGH
00:04
Apr 26
Apr 26
Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27.
Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27, 2026, but
HIGH
23:44
Apr 09
Apr 09
Cramer said Regeneron is "breaking out here," with CEO Leonard Schleifer doing an unbelievable job, and he likes the stock for its pipeline and earnings growth. Company has rising earnings, a strong product pipeline, and positive momentum, making it appealing for investment. Technical breakout and fundamental strength support a LONG position. Pipeline setbacks or regulatory challenges could hinder growth.
13:30
Feb 04
Feb 04
RCA's better-than-expected performance and high clinical trial contribution suggests accelerated adoption of cell-based gene therapies and biosimilars in retina care, a leading indicator for pharmaceutical suppliers. — Indicates that physician education via MSOs is driving faster biosimilar uptake, which could pressure innovator drug revenues sooner.
MED
13:30
Jan 30
Jan 30
Management is confident in the near-term outlook, highlighted by strong commercial execution, a late-stage pipeline (including key readouts in melanoma and myasthenia gravis), and multiple planned FDA approvals in 2026.
HIGH
About REGN Analyst Coverage
Buzzberg tracks REGN (Regeneron Pharmaceuticals) across 11 sources. 1 bullish vs 0 bearish calls from 16 analysts. Sentiment: predominantly bullish (5%). 22 total trade ideas tracked. Latest voices: seedy19tron, DeItaone, Chris Boshoff.